← Back to Search

Glucagon-like peptide-1 receptor agonist

Exenatide for Gestational Diabetes

Phase 4

Recruiting

Led By Maisa Feghali, MD

Research Sponsored by Maisa N. Feghali, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Between 18 and 50 years of age

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 1 week later

Awards & highlights

Study Summary

This trial studies the effects of exenatide to lower blood sugar in pregnant women with type II diabetes, and how it helps the pancreas secrete insulin. It may provide an alternate option to the current drug therapies.

Who is the study for?

This trial is for pregnant women aged 18-50 with gestational diabetes that doesn't yet require medical therapy. Participants must be able to consent and not in their first trimester. Women with low blood counts, gastrointestinal issues, high triglycerides, gallbladder or pancreatic disease, past hypoglycemic treatments, or kidney problems cannot join.Check my eligibility

What is being tested?

The study tests how exenatide affects blood sugar control in pregnant women with gestational diabetes by examining how the body processes the drug and its effectiveness at controlling blood sugar after meals.See study design

What are the potential side effects?

While specific side effects for this trial aren't listed, common ones from exenatide include nausea, vomiting, diarrhea, potential allergic reactions and rarely pancreatitis.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 50 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 week after study enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 week after study enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week after study enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose

Secondary outcome measures

Exenatide

Side effects data

From 2017 Phase 4 trial • 8 Patients • NCT02058940

38%

Death

100%

80%

60%

40%

20%

Study treatment Arm

Exenatide

Trial Design

1Treatment groups

Experimental Treatment

Group I: ExenatideExperimental Treatment1 Intervention

Participant receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Exenatide

2010

Completed Phase 4

~2970

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Maisa N. Feghali, MDLead Sponsor

2 Previous Clinical Trials

114 Total Patients Enrolled

Maisa Feghali, MDPrincipal InvestigatorUniversity of Pittsburgh

1 Previous Clinical Trials

Media Library

Exenatide (Glucagon-like peptide-1 receptor agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05482789 — Phase 4

Gestational Diabetes Research Study Groups: Exenatide

Gestational Diabetes Clinical Trial 2023: Exenatide Highlights & Side Effects. Trial Name: NCT05482789 — Phase 4

Exenatide (Glucagon-like peptide-1 receptor agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05482789 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit of this research higher than 18?

"According to the trial's eligibility parameters, adults aged 18-50 are encouraged to apply."

Answered by AI

Do I meet the criteria to be a part of this clinical evaluation?

"This trial seeks to recruit 13 expectant mothers aged between 18 and 50 who have been diagnosed with gestational diabetes."

Answered by AI

Can you elaborate on the potential risks associated with Exenatide?

"The safety of Exenatide was rated 3 out of 3 because it is a Phase 4 trial, which indicates that this treatment has been approved for public use."

Answered by AI

Are there any open enrollment opportunities for this research project?

"Affirmative. Clinicaltrials.gov indicates that this trial is actively enlisting participants, with the first post dating back to April 12th 2023 and the most recent update on that same day. The researchers are looking for 13 individuals from a single medical facility."

Answered by AI

What is the current enrollment figure for this trial?

"Affirmative, the clinicaltrials.gov website portrays that this trial is still enrolling patients. This project was originally published on April 12th 2023 and underwent its most recent update on the same day; 13 individuals from one medical centre are required for completion of recruitment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Maisa N. Feghali, MD 2023. "Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05482789.

All > Bydureon